Nurix to Showcase CBL-B, AURKA and BRAF Degraders at AACR 2026
Nurix will present two oral and three poster sessions at the AACR Annual Meeting April 17–22, 2026, featuring preclinical data on NX-1607, NRX-4972 and NRX-0305 that demonstrate tumor suppression and CNS activity. CSO Gwenn Hansen will deliver a keynote on induced proximity pharmacology.
1. AACR 2026 Presentation Lineup
Nurix Therapeutics will present at the AACR 2026 Annual Meeting in San Diego from April 17–22 with two oral presentations and three poster sessions showcasing its targeted protein degradation pipeline.
2. Oral and Poster Presentation Details
Oral presentations include 'Designing Effective Degrader Therapeutics' by CSO Gwenn Hansen on April 22 and 'Discovery of CBL-B intramolecular glue inhibitors' by Fred Cohen on April 21. Poster sessions on April 21 will present NRX-4972 (AURKA degrader) efficacy in SCLC models, NRX-0305 (pan-mutant BRAF degrader) activity in intracranial melanoma and glioma, and combination efficacy across Class I–III BRAF mutations.
3. Preclinical Validation of Key Targets
NX-1607, an oral CBL-B inhibitor, has shown reversal of T cell exhaustion and antitumor effects in solid tumor models. NRX-4972 and NRX-0305 demonstrate potent tumor suppression and CNS penetration in preclinical studies, supporting Nurix’s degrader-based therapeutic approach.
4. Induced Proximity Keynote by CSO
Chief Scientific Officer Gwenn Hansen has been selected to speak in the Advances in Diagnostics and Therapeutics session on April 22, delivering insights on induced proximity pharmacology and the future of targeted protein degradation.